There are two Phase II trials underway: NCT03539536, “Study of Telisotuzumab Vedotin (ABBV-399) in Subjects with Previously Treated c-Met+ Non-Small Cell Lung Cancer” and NCT03574753, “Lung-MAP S1400K; c-MET Positive”. The gene discussed is MET; the disease is non-small cell lung carcinoma.